Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C

Table 6 Univariate and multivariate analysis of factors contributing to SVR24 (simeprevir)

Factors	Univariate analysis		Multivariate analysis
	Odds ratio (95%CI)	P value	Odds ratio (95%CI)	P value
Age	0.998 (0.942-1.058)	0.953
Gender (female)	0.330 (0.083-1.314)	0.116
Body mass index (kg/m2)	1.164 (0.934-1.450)	0.175
Prior treatment response (non-NR)	2.955 (0.811-10.764)	0.101
Baseline HCV-RNA (log IU/mL)	0.767 (0.328-1.791)	0.540
Baseline ALT (IU/mL)	0.998 (0.985-1.012)	0.785
Baseline platelets (× 104/mm3)	1.082 (0.953-1.228)	0.224
Baseline hemoglobin (g/dL)	1.257 (0.827-1.910)	0.285
IL28B SNP (TT)	12.593 (1.516-104.576)	0.019	9.677 (1.114-84.087)	0.040
SMV/BW (mg/kg per day)	0.306 (0.054-1.742)	0.182
RBV/BW (mg/kg per day)	1.085 (1.138-3.913)	0.501
PEG-IFN dose reduction (none)	7.250 (1.712-30.700)	0.007	6.557 (1.328-32.377)	0.021
RBV dose reduction (none)	1.556 (0.470-5.160)	0.470
RVR (none)	0.351 (0.075-1.637)	0.183

HCV: Hepatitis C virus; ALT: Alanine aminotransferase; NR: Non-responder; IL28B SNP: Interleukin-28B single nucleotide polymorphism; SMV: Simeprevir; BW: Bodyweight; PEG-IFN: Pegylated interferon; RBV: Ribavirin; RVR: Rapid virological response.